How AI Is Changing Drug Discovery and Pharmaceutical R&D in Europe
Lakshmi, Editorial Team, Pharma Focus Europe
Artificial intelligence is moving from experimental pilot to strategic core in European pharmaceutical research. Early clinical evidence suggests AI-discovered molecules clear Phase I trials at markedly higher rates than conventional candidates, while European regulators are building frameworks that reward transparency and robust data. This article examines where AI is creating measurable value, presents two instructive case studies, and outlines the decisions European C-suite leaders must make to convert promise into productivity.
Europe's R&D Equation Is Being Rewritten
For decades, pharmaceutical research and development has run on a stubborn equation: more than ten years of work, enormous capital commitments and a failure rate that would be unacceptable in almost any other industry. Roughly nine in every ten drug candidates that enter clinical testing never reach patients. For European companies competing against well-funded rivals in North America and Asia, that arithmetic has become harder to defend before boards and investors.
Artificial intelligence is now changing the terms of that equation. What began as a niche capability, used mainly to sift chemical libraries, has become a set of tools that touch nearly every stage of the value chain, from identifying a biological target to designing trials and interpreting their results. The question for European leadership teams is no longer whether AI belongs in R&D. It is how quickly, how safely and how profitably it can be embedded into the way medicines are discovered and developed.
From Gut Instinct to Engineered Insight: AI at the Front of the Pipeline
The earliest and most mature use of AI sits at the very beginning of the pipeline. Traditional discovery relies on screening large numbers of compounds and refining the most promising through repeated cycles of synthesis and testing. Each cycle consumes months. Machine learning models change this by predicting how a molecule is likely to behave before anyone makes it in the laboratory.
Three capabilities stand out. First, target identification: algorithms can mine genomic, proteomic and clinical datasets to surface biological mechanisms that human researchers might overlook. Second, generative chemistry: models can propose entirely new molecular structures that satisfy many design requirements at once, such as potency, selectivity, solubility and safety, rather than optimising one property at a time. Third, predictive toxicology: by flagging molecules likely to cause harm early, AI helps teams abandon weak candidates before they absorb expensive clinical resources.
The strategic value here is not simply speed. It is the ability to make better decisions earlier, when the cost of changing course is lowest. Every poor candidate removed at the design stage is a failed trial that never has to be funded.
The Numbers Behind the Momentum
Enthusiasm for AI has often outpaced evidence, so it is worth looking closely at what the clinical data actually shows. A peer-reviewed analysis published in 2024 offered the first industry-wide view of AI-discovered molecules in human trials, and its findings deserve the attention of every R&D committee.
Since 2015, 75 AI-discovered molecules had entered clinical trials, with the number growing by more than 60 percent year on year. By December 2023, 24 of these molecules had completed Phase I, and 21 were judged successful, a success rate of roughly 80 to 90 percent. Historical industry averages for Phase I sit at approximately 40 to 65 percent.
Phase II tells a more measured story. Of the 10 AI-discovered molecules that had completed this stage, 4 succeeded, a rate of around 40 percent, broadly in line with historical norms. The authors estimated that if these patterns hold, the probability of a molecule succeeding across all clinical phases could rise from 5 to 10 percent to between 9 and 18 percent.
For executives, the message is clear but nuanced. AI appears to be very good at designing molecules that are safe and drug-like, which is precisely what Phase I tests. Proving that a drug works in patients, the central question of Phase II, remains difficult. The sample sizes are still small, and leaders should treat these figures as an early signal rather than a guarantee.
Case Study One: Twelve Months from Concept to Clinic
One of the most cited milestones in the field came in early 2020, when a molecule designed with AI entered a Phase I clinical trial for obsessive-compulsive disorder. The compound was developed through a collaboration between a UK-based AI drug design firm and a Japanese pharmaceutical partner.
The headline was speed. The discovery and optimisation work that typically takes around four and a half years was completed in less than 12 months. Efficiency was equally striking: the clinical candidate was identified after synthesising approximately 350 compounds, compared with an average of about 2,500 using conventional methods.
The molecule did not go on to become an approved medicine, and that detail matters as much as the speed. The case demonstrates that AI can compress the discovery phase dramatically, but it does not remove the scientific uncertainty that follows. For European leaders, the lesson is to value AI for what it reliably delivers today, faster and leaner discovery, while keeping clinical expectations grounded.
Case Study Two: When the Regulator Backs the Algorithm
A second milestone came from Europe itself. In March 2025, the human medicines committee of the European Medicines Agency issued its first qualification opinion on an AI-based methodology. The tool supports pathologists in assessing liver biopsy scans to grade the severity of metabolic dysfunction-associated steatohepatitis, a disease area where trial endpoints depend heavily on consistent tissue analysis.
This was the first time the Agency signalled that data generated with the assistance of an AI tool could be considered scientifically valid evidence in clinical trials. Importantly, the tool operates under human supervision, and it is expected to help researchers obtain clearer evidence of treatment benefit using fewer patients.
The strategic significance extends far beyond one therapeutic area. It shows that European regulators are prepared to accept AI-generated evidence when it is validated, transparent and overseen by qualified experts. Companies that build these qualities into their AI programmes from the outset will be better placed to secure similar recognition.
Beyond the Molecule: Smarter, Leaner Clinical Trials
While discovery attracts most of the headlines, the larger financial prize may lie in clinical development, where the majority of R&D spending is concentrated. Here AI is beginning to influence how trials are designed, populated and monitored.
Predictive models can help sponsors select endpoints, estimate realistic enrolment timelines and identify sites most likely to recruit the right patients. Natural language processing can screen electronic health records to match eligible participants to studies far more quickly than manual review. During a trial, algorithms can monitor incoming data for safety signals and protocol deviations, allowing teams to intervene earlier.
For Europe, where a single study may span many countries, languages and healthcare systems, these capabilities address a long-standing source of delay and cost. The opportunity is to run studies that are smaller, faster and more representative of the patients who will eventually use the medicine. The caveat is equally important: every AI tool that touches trial evidence must be validated with the same rigour regulators expect of any other method.
Europe's Rulebook: Constraint or Competitive Edge?
Europe is often characterised as the world's most demanding regulatory environment for technology. For pharmaceutical AI, that reputation can be turned into an advantage.
The EU Artificial Intelligence Act entered into force on 1 August 2024, establishing a risk-based framework for AI systems. In September 2024, the European Medicines Agency's human and veterinary medicines committees adopted a reflection paper on the use of AI across the medicinal product lifecycle, covering discovery, non-clinical development, clinical trials, precision medicine and post-authorisation activities. The paper emphasises a human-centric approach, active measures against bias and close attention to data integrity.
Clear expectations reduce uncertainty. Organisations that design AI programmes with explainability, documentation and governance built in will find regulatory interactions smoother, and they will produce evidence that stands up to scrutiny in every major market, not only in Europe.
Data: The Fuel Europe Must Learn to Refine
AI is only as good as the data it learns from, and here Europe holds a potentially decisive asset. The continent's public health systems generate rich, longitudinal patient information, but it has historically been fragmented across national borders, languages and formats.
The European Health Data Space Regulation, which entered into force on 26 March 2025, aims to change that. It creates a common framework for the use of electronic health data, including its secondary use for research and innovation. Implementation is phased, with key secondary-use provisions scheduled to apply from March 2029.
Leadership teams should not wait for that date. The organisations that will benefit most are those investing now in data quality, interoperability and privacy-preserving analytics, so that they are ready to draw insight from European health data responsibly the moment access becomes available.
The Boardroom Agenda: Five Decisions for European Leaders
Turning AI from a collection of pilots into a source of sustained advantage requires deliberate choices at the top of the organisation. Five stand out.
- Anchor AI to portfolio strategy. Deploy it where it addresses the most expensive bottlenecks in your pipeline, rather than where it is easiest to demonstrate.
- Treat data as infrastructure. Fund data governance, curation and integration with the same seriousness as laboratory facilities.
- Build hybrid teams. Pair computational scientists with experienced medicinal chemists and clinicians so that algorithmic outputs are interrogated, not simply accepted.
- Engage regulators early. Use scientific advice and qualification procedures to validate AI methods before they underpin pivotal decisions.
- Measure what matters. Track cycle times, cost per candidate and stage-by-stage attrition so that AI investment is judged on productivity, not novelty.
Conclusion: Discipline, Not Hype, Will Decide the Winners
Artificial intelligence is already reshaping how European companies discover and develop medicines. The early evidence is encouraging: faster discovery, leaner chemistry and Phase I success rates that comfortably exceed historical norms. Yet the harder work of proving efficacy in patients remains, and no algorithm has eliminated the fundamental uncertainty of biology.
Europe enters this transition with genuine strengths: world-class science, a regulator willing to accept validated AI evidence and an emerging framework for unlocking health data at continental scale. The companies that win will be those whose leaders combine ambition with discipline, investing in data, governance and talent while holding AI to the same evidential standards as any other scientific method. In the decade ahead, the most valuable advantage will belong not to those who adopt AI first, but to those who adopt it best.